ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)

CAPS Rating: 4 out of 5

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.


Player Avatar Momentum21 (43.39) Submitted: 1/10/2013 2:29:42 PM : Outperform Start Price: $12.98 ISIS Score: +93.23

Twitter trolling pointed this one out...presented at JPM, decent pipeline, solid potential on a couple. Others are sketchy but the ISIS-smn seemed most interesting potential. Just seemed like a must own for the Fund.

Featured Broker Partners